GDI Integrated Facility Services (formerly BioMS Medical Corp and Medwell Capital Corp.) (TSX-V: WMC) is a Canadian provider of janitorial services.
As BioMS Medical Corp, it was a biotechnology company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis. On July 27, 2009 the company announced that its drug, dirucotide, failed to meet its primary endpoint in the Phase III MAESTRO-01 Trial. Medwell discontinued testing, and instead invested in Spectral Diagnostics.
In July 2010, the company rebranded itself as Medwell Capital Corp., with a plan to "directly invest in and advise companies on strategy, financing, mergers & acquisitions (M&A), licensing transactions and undertake technology development." In 2015, it became GDI Integrated Facility Services Inc in a reverse takeover transaction, allowing GDI to go public through its stock exchange listing.
Video GDI Integrated Facility Services
Development
Medwell Capital obtained an exclusive worldwide license to proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The compound, dirucotide (MBP8298), is a synthetic myelin basic protein peptide composed of 17 amino acids that is intravenously injected (every six months) into MS patients as a therapeutic treatment.
Maps GDI Integrated Facility Services
References
- Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial
- The Faces of Canadian Biotech
- Two Steps Forward
External links
- GDI home page
Source of the article : Wikipedia
0 Comments